383865-57-4

Basic information

• Product Name: 4-Methoxy-7-Morpholinobenzo[d]thiazol-2-aMine
• Synonyms: 4-Methoxy-7-Morpholinobenzo[d]thiazol-2-aMine;2-Benzothiazolamine, 4-methoxy-7-(4-morpholinyl)-;2-Amino-4-methoxy-7-morpholinobenzo[d]thiazole
• CAS NO: 383865-57-4
• Molecular Formula: C₁₂H₁₅N₃O₂S
• Molecular Weight: 265.3314
• Mol File: 383865-57-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 4-Methoxy-7-Morpholinobenzo[d]thiazol-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methoxy-7-Morpholinobenzo[d]thiazol-2-aMine(383865-57-4)
• EPA Substance Registry System: 4-Methoxy-7-Morpholinobenzo[d]thiazol-2-aMine(383865-57-4)

Safety Data

• Hazardous Substances Data: 383865-57-4(Hazardous Substances Data)

Usage

General Description

4-Methoxy-7-Morpholinobenzo[d]thiazol-2-aMine is a chemical compound with the molecular formula C13H15N3OS. It is a thiazole compound containing a methoxy group and a morpholino group. 4-Methoxy-7-Morpholinobenzo[d]thiazol-2-aMine has been studied for its potential biological activities, including its use as a building block in the synthesis of pharmaceuticals and agrochemicals. It may also have applications in the field of medicinal chemistry and drug discovery. Additionally, its structure and properties make it a valuable tool for research and development in various scientific fields.

Upstream product

• 383870-59-5 (2-methoxy-5-morpholin-4-yl-phenyl)thiourea 
• 33696-00-3 4-bromo-1-methoxy-2-nitrobenzene 
• 383870-96-0 4-(4-methoxy-3-nitrophenyl)morpholine 
• 383870-88-0 2-methoxy-5-morpholin-4-ylaniline 
• 383870-86-8 1-benzoyl-3-(2-methoxy-5-morpholin-4-yl-phenyl)thiourea 
• 104-94-9 4-methoxy-aniline 
• 955095-74-6 4-(4-methoxyhenyl)morpholine nitric acid salt 

Downstream Products

• 383869-80-5 phenyl (4-methoxy-7-morpholin-4-yl-benzo[d]thiazol-2-yl)carbamate 
• 535924-67-5 2-bromo-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-isonicotinamide 
• 383866-22-6 N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-4-chloromethyl-benzamide 
• 103-67-3 benzyl-methyl-amine 
• 95550-06-4 N(methoxyacetyl)-piperazine 
• 626-56-2 3-Methylpiperidine 
• 626-58-4 4-methylpiperidin 
• 109-01-3 1-methyl-piperazine 
• 100-46-9 benzylamine 
• 4897-50-1 4-piperidinopiperidin 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands

With the aim to obtain potent adenosine A2A receptor (A2AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a chemical building block principle that involved reaction of the appropriate aminobenzothiazole phenyl carbamates with either commercially available or readily synthesized functionalized piperidines. Their affinity and subtype selectivity with regard to human adenosine A1-and A2A receptors were determined using radioligand binding assays. Ki values for human A2AR ranged from 2.4 to 38 nM, with more than 120-fold selectivity over A1 receptors for all evaluated compounds except 13k which had a Ki of 361 nM and 18-fold selectivity. The most potent fluorine-containing derivatives 13e, 13g and 13l exhibited Ki values of 4.9 nM, 3.6 nM and 2.8 nM for the human A2AR. Interestingly, the corresponding values for rat A2AR were found to be four to five times higher. Their binding to A2AR was further confirmed by radiolabeling with 18F and in vitro autoradiography in rat brain slices, which showed almost exclusive striatal binding and complete displacement by the A2AR antagonist ZM 241385. We conclude that these compounds represent potential candidates for the visualization of the A2A receptor and open pathways to novel therapeutic treatments of neurodegenerative disorders or cancer.

4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

The present invention relates to the compound of formula which is 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide, and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compound is useful for the treatment or prevention of Alzheimer's disease, Parkinson's disease, Huntington's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, ADHD (attention deficit hyper-activity disorder), drug addiction to amphetamines, cocaine, opioids, ethanol, nicotine, or cannabinoids, or for the treatment of asthma, allergic responses, hypoxia, ischemia, seizure, substance abuse, or for use as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.

Benzothiazole derivatives with activity as adenosine receptor ligands

The present invention relates to substituted benzothiazole derivitives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.